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Abstract Huntington disease (HD) is an autosomal
dominant neurodegenerative disorder characterised
by chorea, cognitive impairment, dementia and per-
sonality changes, caused by the expansion of a CAG
repeat in the HD gene. Often, patients with a similar
clinical presentation do not carry expansions of the
CAG repeat in this gene [Huntington disease-like
(HDL) patients]. We report the genetic analysis of
107 Portuguese patients with an HDL phenotype.
The HDL genes PRNP and JPH3, encoding the
prion protein and junctophilin-3, respectively, were
screened for repeat expansions in these patients.
Given the partial clinical overlap of SCA17, DRPLA
and neuroferritinopathy with HD, their causative
genes (TBP, ATN1, and FTL, respectively) were also
analysed. Finally, repeat expansions in two candidate
genes, CREBBP and POU3F2, which encode the
nuclear transcriptional coactivator CREB-binding
protein and the CNS-specific transcription factor N-
Oct-3, respectively, were also studied. Expansions of
the repetitive tracts of the PRNP, JPH3, TBP,
ATN1, CREBBP and POU3F2 genes were excluded
in all patients, as were sequence alterations in the
FTL gene. Since none of the genes already included
in the differential diagnosis of HD was responsible
for the disease in our sample, the genetic heteroge-
neity of the HDL phenotype is still open for inves-
tigation.
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Introduction
Huntington disease (HD) is an autosomal dominant
progressive neurodegenerative disorder, usually of
adult onset, associated with involuntary choreic
movements, motor problems, cognitive impairment
and personality alterations. HD is caused by the
expansion of a CAG repeat in the coding region of
the HD gene, located on chromosome 4p16.3 (The
Huntington Collaborative Research Group 1993).
Normal alleles contain 6–35 CAGs and pathogenic
alleles carry ‡36 CAGs (The American College of
Medical Genetics 1998). However, some patients with
Huntington disease-like (HDL) presentations do not
carry any expansion of the (CAG)n tract in the HD
gene. Sequence alterations in two loci responsible for
a HDL phenotype (PRNP and JPH3) have already
been identified: for PRNP (HDL1), a 192-nucleotide
insertion within the prion protein gene (PRNP),
localised in chromosome 20p (Xiang et al. 1998), that
gives rise to an expanded prion protein with eight
extra octapeptide repeats (Moore et al. 2001); for
JPH3 (HDL2), a CAG/CTG repeat in the juncto-
philin-3 gene (JPH3) (Holmes et al. 2001), localised
in chromosome 16q23–24 (Kambouris et al. 2000;
Nishi et al. 2000). Other possible causative genes re-
main unknown, although a gene associated with an
autosomal recessive transmission of HDL phenotype
has been mapped to chromosome 4p15.3 (Kambouris
et al. 2000), and some evidence suggests that CAG
repeat expansions in unidentified genes could also be
responsible for a similar clinical presentation (Mar-
golis et al. 2001).
The CREB-binding protein (CBP) is a nuclear
transcriptional coactivator protein that has been found
in the characteristic neuronal intranuclear inclusions of
patients with several polyglutamine expansion diseases
(McCampbell et al. 2000; Nucifora et al. 2001). Point
mutations in the CREBBP gene have also been asso-
ciated with Rubinstein–Taybi syndrome (Petrij et al.
1995). Similarly to HD, SBMA and other neurode-
generative disease genes, the CREBBP gene contains a
CAG repeat tract. The POU3F2 gene, encoding the
central nervous system (CNS)-specific transcription
factor N-Oct-3, is another gene also containing a CAG
repeat in its coding region (Atanasoski et al. 1995).
This makes CREBBP and POU3F2 interesting candi-
date genes for autosomal dominant late-onset neuro-
degenerative disorders.
In movement disorders there is some clinical overlap
between different diseases. This is the case for some
forms of autosomal dominant cerebellar ataxia, spe-
cifically spinocerebellar ataxia type 17 (SCA17) (Koide
et al. 1999; Nakamura et al. 2001), and dentatorubro-
pallidoluysian atrophy (DRPLA) (Koide et al. 1994),
which may show clinical features similar to those of
HD, namely dementia, chorea, Parkinsonism and dys-
tonia. SCA17 is caused by an expansion of a CAA/
CAG repeat segment on the TATA-binding protein
gene (TBP), and DRPLA is also caused by an expan-
sion of a (CAG)n in the gene encoding athrophin-1
(ATN1). Another example of a movement disorder
sharing some clinical features with HD is neuroferr-
itinopathy. This disorder is characterised by extrapy-
ramidal dysfunction including choreoathetosis,
dystonia, spasticity and rigidity, most often without
cognitive decline (Curtis et al. 2001). The dominant
mutations responsible for neuroferritinopathy are ei-
ther small insertions in the coding region of the ferritin
light polypeptide gene (FTL), causing frameshifts and
originating proteins with different C-termini (Curtis
et al. 2001), or missense mutations in conserved regions
(Maciel et al. 2005).
As we have previously reported (Costa et al. 2003),
among our series of cases for HD diagnosis, we found a
high number of HD mutation-negative patients who
had both a family history and typical HD clinical fea-
tures. Here, we describe a series of 107 HDL patients of
Portuguese origin, who do not present (CAG)n expan-
sions in the HD gene. In order to find the genetic cause
of the HDL phenotype in these patients, we investi-
gated the presence of repeat expansions in the two
described HDL loci (PRNP and JPH3) and in the TBP,
ATN1, CREBBP and POU3F2 genes. Additionally, in
search of potential sequence alterations, we have se-
quenced the entire coding region of the FTL gene, as
well as its iron responsive element (IRE) region.
Materials and methods
Subjects
From all the HD diagnostic tests performed in our
laboratory between 1998 and the end of December
2003 (requested mostly by neurologists for confirma-
tion or exclusion of a clinical diagnosis), a total of 107
samples of unrelated Portuguese patients was negative
for a CAG repeat expansion in the HD gene. After the
study was reviewed and approved by the research
ethics committee of the Institute for Molecular and
Cell Biology, and informed consent of the patients was
obtained, we included these patients in the current
study. For a gross clinical characterisation of the dis-
ease we have considered one group of ‘‘movement
disorder’’ patients with the following symptoms in their
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clinical record: chorea, involuntary movements, trem-
ors, Parkinsonism, dystonia, pyramidal and/ or extra-
pyramidal signs; another group with a mainly
‘‘psychiatric disorder’’ with the features: dementia,
behaviour alterations, psychosis, depression and/ or
suicidal thoughts; and a third group with both types of
manifestations. The existence of a family history of a
similar disease was ascertained, and registered as
present, absent or unknown. Additional laboratory
investigations performed by the clinicians were re-
quested and registered when provided (20.6% of the
cases under study).
Genetic analysis
Genomic DNA was extracted from blood lymphocytes
by standard methods (Sambrook et al. 1989). Repeat
expansions causing HD or other disorders with a similar
clinical presentation were screened in the probands: the
CAG/CTG or CAA/CAG repeats in the HD, TBP,
ATN1 and JPH3 genes were amplified using the pairs of
primers RS1/WP2 (Andrew et al. 1994a), TBP-F/TBP-
R (Nakamura et al. 2001), B37CAGrepeat primers
(Koide et al. 1994) and L237-1/L237-2 (Holmes et al.
2001), respectively, using the published PCR conditions
for each primer pair. For screening of the HD and
ATN1 genes, a positive DNA control containing 94 and
66 CAGs, respectively, was included in each set of PCR
reactions. According to the guidelines for the molecular
diagnosis of HD (The American College of Medical
Genetics 1998), in the case of normal homoallelic
individuals (both alleles with the same repeat size) at
the HD gene, the presence of high repeat expansions
was first excluded by a second PCR reaction including
both the CAG and the CCG repeats (Andrew et al.
1994b), and finally by genomic DNA southern blotting
(Guida et al. 1996). The CAA/CAG repeat tracts on the
CREBBP and POU3F2 genes were also studied by
PCR amplification using the primer pairs CBP1
(5¢GTACCGAGAAATGTTACG3¢)/CBP2 (5¢GCTG
CTGGAACTGGCCGTG3¢) and POU3F2_1 (5¢GAG
ACGAGCTGCACGGGCCAG3¢)/POU3F2_2(5¢GG
CGTGGTGCACCAGATGCG3¢), respectively. The
PCR reaction (similar to that used for the HD gene)
was performed in a final volume of 12.5 ll, 200 lM
dNTPs, 1.5 mM MgCl2, primers at 200 lM and 0.75
units of Taq DNA polymerase (Fermentas, St. Leon
Rot, Germany), using an initial denaturation period of
5 min at 94C followed by 35 cycles of 1 min at 94C,
1 min at 56C (CREBBP) or 63C (POU3F2), 1 min at
72C, and an elongation for 5 min at 72C. All the PCR
products containing the CAG or the CAA/CAG
repeats were separated in a 6% denaturing polyacryl-
amide gel, transferred to a nylon membrane and hy-
bridised with a (CAG)15 oligonucleotide previously
labelled with 32P. Repeat sizes were visualised by
autoradiography, by which no smears (corresponding to
potential high repeat expansions) were observed in the
normal homoallelic individuals. The octapeptide repeat
on the PRNP gene and the FTL gene were studied
using methods previously described by Beck et al.
(2001) and Curtis et al. (2001), respectively.
Statistical analysis
Chi-squared analysis was used to test different gender
proportions for each group of patients. Student’s t-test
was used to compare mean age at onset in two groups
(male/female, each pair of ‘‘type of disease’’ and each
pair of ‘‘family history’’) using a 95% confidence
interval of the difference. A one-way ANOVA test was
used to compare mean age at onset between subgroups
of type of disorder or of family history. All these tests
were performed using the statistic SPSS 11.0 package.
A P-value < 0.05 was considered statistically signifi-
cant.
Results
The 107 Portuguese patients for whom we have
molecularly excluded HD were referred to our labo-
ratory mainly by neurologists (91.4%). Three infantile
cases (age at onset 3, 5 and 7 years) and one juvenile
case (age at onset 16 years) of HDL disease were in-
cluded in this series. Additional clinical biochemical
and molecular analyses allowed the a posteriori
establishment of a different diagnosis for four of the
HDL patients: one case of CNS vasculitis, one case of
primary hypoparathyroidism, and two cases of reces-
sive mitochondrial encephalopathy.
The majority of patients presented both movement
and psychiatric symptoms (ntotal =58; 54.3%) (Fig. 1),
and most had a positive family history of the disease
(n =48; 44.8%). The largest subgroup of patients in our
HDL population was that with a family history (com-
patible with an autosomal dominant mode of trans-
mission) of a movement and psychiatric disorder
(n =27; 25.2% of the total series and 45.8% of the
movement and psychiatric group; Fig. 1).
In relation to the type of disorder, the three groups of
patients differed significantly in their mean age at onset
(one-way ANOVA test, P =0.011). This difference is
due to a higher mean age at onset of patients with
movement and psychiatric features (53.5±17.9 years) in
relation to patients showing only a movement disorder
J Hum Genet (2006) 51:645–651 647
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(39.4±21.8 years)—Student’s t-test, P =0.005—or to
those presenting only psychiatric impairment
(40.7±11.8 years)—Student’s t-test, P =0.077 (Table 1).
The age at onset of HDL patients did not vary
depending on the existence of a present, absent or un-
known family history. The gender proportions did not
differ among all the groups characterised either by type
of disorder, or by family history. However, the mean
age at onset was significantly higher in female patients
(54.1±18.1 years) than in males (38.5±19.0 years),
P =0.001 (Student’s t-test). In the subgroup of patients
more represented in our HDL population (those with a
family history of a movement and psychiatric disorder),
the disease had a mean age at onset of 50.7±19.2 years
(range: 20–78 years)—which can be considered the
typical clinical presentation of HD (Table 1). In con-
trast, the smallest subgroup of patients (n =2) included
those that showed only psychiatric alterations and an
unknown family history (with a mean age at onset of
43.0 years) (Table 1).
By definition, we have excluded expansions of the
CAG repeat in the HD locus for our entire HDL
population; all patients presented normal or normal
unstable alleles between 10 and 31 repeats. The two
loci described as responsible for HDL disease—PRNP
(HDL1) and JPH3 (HDL2)—were also excluded in
our patients. No expansions of the octapeptide repeat
were found in the PRNP gene. The CAG/CTG repeats
in the JPH3 gene were all within the normal range,
varying between 11 and 19 units, allele 14 being the
most frequent (52.3%) followed by alleles with 16 re-
peats (27.6%). Homoallelism for the normal size was
found in 35.5% of cases, most often (94.7%) for the
commonest alleles (76.3% for allele 14, and 18.4% for
allele 16); in these cases the corresponding band ob-
served was always of higher intensity than those seen in
cases of normal heteroallelism. Two other loci causing
disorders with some clinical overlap with HD—TBP
and ATN1—were also screened and no expansions of
their repetitive tracts were found in the Portuguese
HDL patients: alleles for the TBP gene varied between
29 and 41 triplets, the most frequent allele being the
(CAA/CAG)38 repeat (34.1%), and 24.3% of cases
were shown to be normal homoallelics (61.5% of which
for allele 38); the (CAG)n at the ATN1 locus was
distributed between 7 and 21 trinucleotides, with a
peak at 15 CAGs (31.8%). The CAA/CAG repeat
tracts in the coding regions of the CREBBP and
POU3F2 genes were also screened for potential
expansions. However, these repeat tracts were not
polymorphic, showing 25 and 18 repeats in all patients,
respectively. No smears (corresponding to potential
large repeat expansions) were observed in the autora-
diographs. Moreover, taking into account the similarity
of clinical features between HD and neuroferritinop-
athy (Curtis et al. 2001), its causative gene—FTL—was
entirely sequenced for all the HDL patients. No se-
quence alterations were observed either in the coding
region, in the iron-responsive element (IRE) localised
in the 5¢ untranslated region, or in the acceptor or
donor splice sites of the FTL gene.
Table 1 Clinical features and family history of Huntington disease-like (HDL) patients
Family history Type of disorder Total (%)
Movement and psychiatric Movement Psychiatric
% Age at onset % Age at onset % Age at onset
Range Mean SD Range Mean SD Range Mean SD
Present 24.8 (20–78) 50.7 19.2 14.3 (5–80) 47.3 21.5 5.7 (25–54) 37.8 12.1 44.8
Absent 15.2 (25–83) 57.7 18.4 14.3 (3–74) 35.8 22.0 3.8 (33–58) 45.5 17.7 33.3
Unknown 14.3 (30–69) 53.1 13.0 5.7 (7–51) 28.3 18.5 1.9 (43) 43.0 – 21.9
Total 54.3 (20–83) 53.5 17.9 34.3 (3–80) 39.4 21.8 11.4 (25–58) 40.7 11.8 –
Fig. 1 Type of disorder related with the family history of
Portuguese Huntington disease-like (HDL) patients. Frequency
of patients grouped by presence, absence or unknown family
history for each type of disorder. Total Frequency of patients
grouped by type of disorder
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Discussion
The availability of a genetic test for HD has allowed
physicians not only to confirm the clinical diagnosis of
patients with an established family history of HD, but
also to exclude some cases presenting atypical symp-
toms or an unclear family history of the disease.
In this study we tried to characterise, clinically and
genetically, a series of Portuguese patients with an
HDL phenotype who did not carry a (CAG)n expan-
sion in the HD locus. Our sample of HDL patients
includes a large proportion of cases presenting both
movement and psychiatric impairment, plus a family
history of the disease (25.2%), which could be con-
sidered as true HD phenocopies.
In relation to the type of disorder, patients carrying
both a movement disorder and psychiatric symptoms
usually start to present the disease at a later age
(53.5±17.9 years) than those presenting only one type
of symptomatology (39.4±21.8 years for movement
disorders, and 40.7±11.8 years for psychiatric mani-
festations). The cases of earliest onset of disease in-
cluded in our study, three infantile and one juvenile
case, all had an exclusively motor presentation, and
could overlap with metabolic or mitochondrial disor-
ders (which have been excluded), juvenile Parkinson’s
disease or pantothenate kinase-associated neurode-
generation, which should be tested for these patients in
the future.
Screening of the Portuguese HDL patients for
octapeptide-insertions or CAG/CTG repeat expan-
sions, respectively, for the PRNP and JPH3 loci did not
reveal any expansion in these repetitive tracts. The
insertion of octapeptides in the coding region of the
PRNP gene has been reported in only one family
(Moore et al. 2001; Xiang et al. 1998) and, as in the
current report, other studies did not find this type of
mutation in the PRNP gene (Bauer et al. 2004; Stevanin
et al. 2003), which suggests that this must be a very rare
genetic cause of disease in HDL patients. Nevertheless,
the possible existence of HDL-causative point muta-
tions in the PRNP gene in our sample remains open.
Our results regarding the absence of CAG/CTG repeat
expansions in the JPH3 gene are also in agreement with
other reports (Bauer et al. 2002; Stevanin et al. 2002),
suggesting that the mutation responsible for HDL2 is
not found, so far, in Caucasian patients. The fact that
this mutation was found only in patients of African
ancestry could be explained by a common origin of the
mutation or by a genetic predisposition for expansion in
this specific population (Holmes et al. 2001; Stevanin
et al. 2003). Analysis of the JPH3 locus should be of
particular interest in patients of African origin with an
HDL phenotype who do not present a CAG repeat
expansion in the HD gene.
In contrast to other recent reports, showing that
CAA/CAG repeat expansions at the TBP gene are
responsible for HDL phenotype (Bauer et al. 2004;
Cellini et al. 2004; Stevanin et al. 2003; Toyoshima
et al. 2004), we did not find any repeat larger than 41
triplets, and until now only one intermediate allele
carrying 43 repeats has been found in a Portuguese
patient presenting ataxia and mental retardation (Sil-
veira et al. 2002). This suggests that such mutations will
be a rare cause of disease in our population.
Given the partial clinical overlap between DRPLA
and HD and the finding of four Portuguese DRPLA
families, all sharing the same haplotype with the Jap-
anese patients (Martins et al. 2003), we determined the
(CAG)n tract size on the ATN1 gene for all our HDL
patients, but no expansions of this tract were found.
This result is in accordance with other studies reporting
no (CAG)n expansions in the ATN1 gene in HDL
patients (Stevanin et al. 2002, 2003), showing that this
mutation is rare in patients of non-Asian origin.
In order to exclude further mutations that could be
responsible for movement disorders sharing some
clinical presentation with HD, we sequenced the entire
FTL gene, the gene responsible for neuroferritinopa-
thy (Curtis et al. 2001). The adenine insertion at
nucleotides 460–461, as well as other possible sequence
alterations in the entire coding region of the gene and
in the 5¢ IRE-comprising region, were excluded in our
sample. This is, to our knowledge, the first report of a
large series of HDL patients in whom mutation of the
FTL gene has been excluded. The results suggest that
neuroferritinopathy will rarely overlap with HD, or
that neuroferritinopathy is rare in the Portuguese
population; we have previously identified one neurof-
erritinopathy family of gypsy origin, carrying a mis-
sense mutation in the FTL gene (Maciel et al. 2005).
Our study also demonstrated the first exclusion of
possible expansions of the CAG repeat tracts in two
candidate genes—CREBBP and the POU3F2—in pa-
tients with an HDL phenotype; these repeat tracts
revealed to be stable in our series of Portuguese
patients, although mutations in these genes other than
expanded repetitive tracts may potentially still be
responsible for the HDL presentation. Additional
improvement of the detection of repeat expansions in
the HDL genes and in other candidate genes is still
needed.
In conclusion, in our series of HDL patients, we
have excluded mutations in: (1) the described HDL
loci (PRNP and JPH3); (2) genes responsible for
movement disorders with clinical features similar to
J Hum Genet (2006) 51:645–651 649
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HD, namely the TBP, ATN1 and the FTL genes; and
(3) novel candidate genes containing CAG repeat
tracts—CREBBP and POU3F2. None of the genes
already included in the differential diagnosis of HD
was responsible for the disease in our sample, nor were
any of the other possible causative genes we tested.
Given previous similar reports and the high clinical
heterogeneity of these patients, we suggest that the
JPH3 gene should be analysed in patients of African
origin, the ATN1 gene in Asian patients, and the TBP
gene in patients presenting some cerebellar symptoms.
Overall, the genetic cause of disease in patients
showing typical HD symptoms and a family history of
the disease (representing 24.5% of our population)
remains unknown, suggesting that HDL disorders are
clinically and genetically heterogeneous.
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L, Coutinho P, Sequeiros J, Silveira I (2003) Portuguese
families with dentatorubropallidoluysian atrophy (DRPLA)
share a common haplotype of Asian origin. Eur J Hum
Genet 11:808–811
McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M,
Walcott J, Merry D, Chai Y, Paulson HL, Sobue G, Fisch-
beck KH (2000) CREB-binding protein sequestration by
expanded polyglutamine. Hum Mol Genet 9:2197–2202
Moore RC, Xiang F, Monaghan J, Han D, Zhang Z, Edström L,
Anvret M, Prusiner SB (2001) Huntington disease phenocopy
is a familial prion disease. Am J Hum Genet 69:1385–1388
Nakamura K, Jeong S-Y, Uchihara T, Anno M, Nagashima K,
Nagashima T, Ikeda S, Tsuji S, Kanazawa I (2001) SCA17, a
novel autosomal dominant cerebellar ataxia caused by an
expanded polyglutamine in TATA-binding protein. Hum
Mol Genet 10:1441–1448
650 J Hum Genet (2006) 51:645–651
123
Nishi M, Mizushima A, Nakagawara K, Takeshima H (2000)
Characterization of human junctophilin subtype genes.
Biochem Biophys Res Commun 273:920–927
Nucifora FC, Sasaki M, Peters MF, Huang H, Cooper JK,
Yamada M, Takahashi H, Tsuji S, Troncoso J, Dawson VL,
Dawson TM, Ross CA (2001) Interference by huntingtin
and atrophin-1 with CBP-mediated transcription leading to
cellular toxicity. Science 291:2423–2428
Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC,
Masuno M, Tommerup N, van Ommen GJ, Goodman RH,
Peters DJ, Breuning MH (1995) Rubinstein–Taybi syn-
drome caused by mutations in the transcriptional co-acti-
vator CBP. Nature 376:348–351
Sambrook J, Fritsh EF, Maniatis T (1989) Molecular cloning—a
laboratory manual, 2nd edn. Cold Spring Harbor Labora-
tory Press, Cold Spring Harbor, NY
Silveira I, Miranda C, Guimarães L, Moreira MC, Alonso I,
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